Zyden Gentec Ltd
Zyden Gentec Limited, incorporated in India, Listed on the Bombay Stock exchange Limited, the company is engaged in manufacturing of Drug intermediates
- Market Cap ₹ 4.83 Cr.
- Current Price ₹ 0.87
- High / Low ₹ /
- Stock P/E 8.47
- Book Value ₹ 2.37
- Dividend Yield 0.00 %
- ROCE -0.98 %
- ROE -2.06 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Stock is trading at 0.37 times its book value
Cons
- Company might be capitalizing the interest cost
- Company has high debtors of 2,656 days.
- Working capital days have increased from 991 days to 2,192 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | TTM | |
---|---|---|---|---|
9.51 | 14.08 | 1.59 | 0.00 | |
12.42 | 14.98 | 2.90 | 0.08 | |
Operating Profit | -2.91 | -0.90 | -1.31 | -0.08 |
OPM % | -30.60% | -6.39% | -82.39% | |
0.10 | 0.94 | 1.32 | 0.68 | |
Interest | 1.24 | 0.40 | 0.03 | 0.03 |
Depreciation | 0.41 | 0.26 | 0.25 | 0.00 |
Profit before tax | -4.46 | -0.62 | -0.27 | 0.57 |
Tax % | -8.07% | 0.00% | 0.00% | |
-4.10 | -0.62 | -0.27 | 0.57 | |
EPS in Rs | -0.74 | -0.11 | -0.05 | 0.11 |
Dividend Payout % | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -100% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 5800% |
Stock Price CAGR | |
---|---|
10 Years: | -7% |
5 Years: | % |
3 Years: | % |
1 Year: | % |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | -2% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Sep 2015 | |
---|---|---|---|---|
Equity Capital | 11.11 | 11.11 | 11.11 | 11.11 |
Reserves | 1.96 | 1.62 | 1.37 | 2.05 |
11.25 | 11.87 | 9.84 | 7.56 | |
2.07 | 8.21 | 9.01 | 10.80 | |
Total Liabilities | 26.39 | 32.81 | 31.33 | 31.52 |
8.75 | 8.53 | 8.25 | 8.25 | |
CWIP | 0.08 | 0.00 | 0.00 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.01 |
17.56 | 24.28 | 23.08 | 23.26 | |
Total Assets | 26.39 | 32.81 | 31.33 | 31.52 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | |
---|---|---|---|
-1.78 | 3.67 | 0.26 | |
-6.44 | 0.37 | 1.34 | |
8.08 | -4.03 | -1.69 | |
Net Cash Flow | -0.14 | 0.01 | -0.09 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | |
---|---|---|---|
Debtor Days | 82.52 | 291.90 | 2,656.01 |
Inventory Days | 93.09 | 35.60 | 122.26 |
Days Payable | 39.37 | 207.45 | 1,467.09 |
Cash Conversion Cycle | 136.24 | 120.05 | 1,311.18 |
Working Capital Days | 495.49 | 284.64 | 2,192.30 |
ROCE % | -0.90% | -0.98% |
Documents
Announcements
- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 29 Mar 2016
- Financial Results for December 31, 2015 22 Feb 2016
-
Adjournment of Board Meeting
13 Feb 2016 - Due to some unavoidable circumstances the Board have decided to postponed and adjourned the meeting for considerations and Approval of Un - Audited Financial Results …
- Financial Results for Sept 30, 2015 (Clear Copy) 1 Jan 2016
- Outcome of Board Meeting 14 Nov 2015